Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
Phase 1 Terminated
5 enrolled 11 charts
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Phase 1 Terminated
17 enrolled
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
DIPG
Phase 1 Terminated
4 enrolled
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
Phase 1 Completed
17 enrolled 12 charts
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Phase 1 Completed
298 enrolled
PanRVD
Phase 1 Completed
21 enrolled
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Phase 1 Terminated
16 enrolled
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Phase 1 Completed
14 enrolled
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Phase 1 Completed
46 enrolled
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Phase 1 Completed
36 enrolled
Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
14 enrolled
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
Phase 1 Completed
15 enrolled
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
Phase 1 Completed
37 enrolled
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
Phase 1 Completed
46 enrolled
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Phase 1 Completed
10 enrolled
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
Phase 1 Terminated
2 enrolled
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Phase 1 Completed
29 enrolled
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
Phase 1 Completed
77 enrolled
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Phase 1 Completed
32 enrolled
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Terminated
19 enrolled
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Phase 1 Completed
23 enrolled
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
Phase 1 Terminated
7 enrolled
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
Phase 1 Completed
40 enrolled
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Phase 1 Completed
38 enrolled
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Phase 1 Terminated
8 enrolled
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Phase 1 Completed
30 enrolled
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1 Terminated
12 enrolled
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
Phase 1 Completed
20 enrolled 5 charts
Panobinostat/Velcade in Multiple Myeloma
Phase 1 Terminated
12 enrolled
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase 1 Withdrawn
BUS48T
Phase 1 Completed
3 enrolled
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
9 enrolled
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Phase 1 Unknown
24 enrolled
LBH589 and Gemcitabine in the Treatment of Solid Tumors
Phase 1 Terminated
17 enrolled
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1 Completed
11 enrolled
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Phase 1 Unknown
36 enrolled
BEL
Phase 1 Completed
14 enrolled
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Phase 1 Completed
14 enrolled
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
Phase 1 Completed
4 enrolled
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
Phase 1 Terminated
3 enrolled
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
Phase 1 Unknown
36 enrolled
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
Phase 1 Completed
40 enrolled
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
Phase 1 Terminated
108 enrolled